|
 |
Calcitonin-salmonThis page contains recent news articles, when available, and an overview of Calcitonin-salmon but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.BOTHELL, Wash., Feb. 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. , a leader in developing therapeutics using advanced molecular ... Free with registration - PR Newswire - AccessMyLibrary.com … Tentative FDA Approval of Generic Calcitonin-Salmon Nasal Spray... - Dec 15, 2008 BOTHELL, WA--(Marketwire - December 15, 2008) - MDRNA, Inc. ( NASDAQ : MRNA) announced today that the US Food and Drug Administration (FDA) has granted ... marketwire.com Generic name: Calcitonin-salmon - Dec 1, 2005 Miacalcin is a synthetic form of calcitonin, a naturally occurring hormone produced by the thyroid gland. Miacalcin reduces the rate of calcium loss from ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com NASTECH COMPLETES FDA PAI FOR CALCITONIN-SALMON … - Apr 1, 2006 Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), Bothell, Wash., a leader in developing therapeutics using advanced molecular biology-based drug delivery ... Free with registration - Biotech Business - AccessMyLibrary.com … Tentative FDA Approval Of Generic Calcitonin-Salmon Nasal Spray... - Dec 17, 2008 MDRNA, Inc. (NASDAQ: MRNA) announced that the US Food and Drug Administration (FDA) has granted tentative approval of MDRNA's Abbreviated New Drug ... Medical News Today - Medical News Today (press release) Nastech Provides Calcitonin Salmon Nasal Spray Complete Response to … - Sep 29, 2006 BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. announced today it has submitted a complete response to the FDA's ... Free with registration - PR Newswire - AccessMyLibrary.com Bloomberg Printer-Friendly Page - Aug 4, 2008 BOTHELL, Wash.--(BUSINESS WIRE)--August 04, 2008 MDRNA, Inc. (Nasdaq: MRNA) today reported financial results for the three- and six-month periods ended June ... Bloomberg … Company Receives FDA Communication Concerning Calcitonin-Salmon … - Jul 16, 2006 Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that written notification from the FDA was received on July 10, 2006 stating that ... Medical News Today - Medical News Today (press release) … adjunct Calcitonin-Human Calcitonin-Salmon Bone resorption... - Aug 1, 2006 Calcitonin (kal-si-TOE-nin) is used to treat Paget's disease of bone. It also may be used to prevent continuing bone loss in women with postmenopausal ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … Code - 77 Ill. Adm. Code 790.1830 CALCITONIN, SALMON (Repealed) - Aug 10, 2005 77 Ill. Adm. Code 790.1830 CALCITONIN, SALMON (Repealed) Repealed. (Source: Repealed at 17 Ill. Reg. 15916, effective September 20, 1993) ... Pay-Per-View - Illinois Administrative Code - Loislaw Intranasal calcitonin-salmon (Nastech Pharmaceutical).(Non-approvable... - Aug 1, 2006 ...* Intranasal calcitonin-salmon (Nastech Pharmaceutical) for the treatment of post-menopausal osteoporosis. Free with registration - Formulary - AccessMyLibrary.com FORTICAL NASAL SPRAY FOR OSTEOPOROSIS LAUNCHED. - Oct 1, 2005 Upsher-Smith Laboratories, Inc. Minneapolis, has launched new Fortical(R) calcitonin-salmon (rDNA origin) Nasal Spray, an effective treatment option for ... Entrepreneur FDA rejects Nastech nose spray medication for osteoporosis - Jul 14, 2006 By NICK EATON. Nastech Pharmaceutical Co. Inc. said Thursday that the Food and Drug Administration has rejected the Bothell-based company's ... Seattle Post-Intelligencer - Seattle Post Intelligencer … Release: Nastech Provides Calcitonin Salmon Nasal Spray Complete … - Sep 29, 2006 Nastech Provides Calcitonin Salmon Nasal Spray Complete Response to FDA. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Shijiazhuang Pharma and Unigene to set up JV to produce osteoporosis ... - Jan 4, 2008 An effective osteoporosis treatment, calcitonin salmon is currently produced ... The joint venture is expected to produce 70 million calcitonin salmon ... Free with registration - China Business News - AccessMyLibrary.com Article: NASTECH COMPLETES FDA PAI FOR CALCITONIN-SALMON … - Apr 1, 2006 NASTECH COMPLETES FDA PAI FOR CALCITONIN-SALMON MANUFACTURE. ... find Biotech Business articles. Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), ... Pay-Per-View - Biotech Business - HighBeam Research A MATTER OF TRUST: OXYTOCIN IN NASAL SPRAY.(News) | Article … - Jun 1, 2005 A MATTER OF TRUST: OXYTOCIN IN NASAL SPRAY.(News) ... find The Cincinnati Post (Cincinnati, OH) articles. Byline: Joseph B. Verrengia Associated Press Trust ... Pay-Per-View - Cincinnati Post - HighBeam Research … for Commercial Manufacturing of Calcitonin-Salmon Nasal Spray for... - Feb 28, 2006 Nastech's Facility Approved for Commercial Manufacturing of Calcitonin-Salmon Nasal Spray for Treatment of Osteoporosis. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: AUDIO from Medialink and GlaxoSmithKline: A New … - Sep 28, 2007 AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: MRNA & AOAG "Bullinadvantage.com Alert". - M2 … - Dec 16, 2008 MRNA & AOAG "Bullinadvantage.com Alert". from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Intranasal calcitonin-salmon (Nastech Pharmaceutical).(Non-approvable... - Aug 1, 2006 ...* Intranasal calcitonin-salmon (Nastech Pharmaceutical) for the treatment of post-menopausal osteoporosis. $4.95 - Formulary - ECNext Press Release: Nastech Pharmaceutical Company Announces Initiation … - Oct 1, 2007 PR Newswire; February 28, 2006 ; 700+ words ... ... approval process necessary to bring Nastech's calcitonin-salmon nasal spray to the market. ... Pay-Per-View - PR Newswire - HighBeam Research Article: FORTICAL NASAL SPRAY FOR OSTEOPOROSIS LAUNCHED. - … - Oct 1, 2005 Upsher-Smith's Fortical (calcitonin salmon [rDNA origin]) Nasal Spray was approved for treating postmenopausal osteoporosis in women greater than five years ... Pay-Per-View - Biotech Business - HighBeam Research Osteoporosis; US FDA completes preapproval inspection of Nastech … - Mar 28, 2006 Successful completion of this PAI enables Nastech to manufacture calcitonin-salmon nasal spray for commercial use upon FDA approval of the company's ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Article: GENERIC DRUGS' COMMON STRUGGLE NASTECH'S CASE … - Apr 14, 2008 GENERIC DRUGS' COMMON STRUGGLE NASTECH'S CASE SHOWS WHY MEDICINE, DESPITE LAW, IS SLOW TO REACH MARKET.(Business) ... find Seattle Post-Intelligencer ... Pay-Per-View - Seattle Post-Intelligencer - HighBeam Research Press Release: Stonegate Report About Unigene Laboratories Inc. - PR ... - Mar 13, 2008 Stonegate Report About Unigene Laboratories Inc. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Q2 2006 Nastech Pharmaceutical Earnings Conference Call - Part 1. - Aug 2, 2006 I'd like to begin with our generic calcitonin salmon nasal spray program. ... First, I want to make it clear that the calcitonin salmon nasal spray product ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Press Release: FDA Acts to Avoid Shortage and Strengthen the Safety... - Nov 21, 2008 FDA Acts to Avoid Shortage and Strengthen the Safety of Sucraid Agency expedites approval of orphan drug and increases protections forusers. from M2 ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Nastech to Manufacture Nascobal(R) Nasal Spray for … - Oct 17, 2005 Nastech to Manufacture Nascobal(R) Nasal Spray for QOL Medical. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Stonegate Report About Unigene Laboratories Inc.( … - Mar 13, 2008 Stonegate Report About Unigene Laboratories Inc.(Report) from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Nastech Announces Publication Demonstrating Lower … - Sep 20, 2005 Nastech Announces Publication Demonstrating Lower Weight in Preclinical Model Following PYY3-36 Administration. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: MDRNA, Inc. (NASDAQ: MRNA) Hot Stock on the Move! - … - Dec 16, 2008 MDRNA, Inc. (NASDAQ: MRNA) Hot Stock on the Move! from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Nastech Pharmaceutical Company Inc. Announces … - Jan 26, 2005 Nastech Pharmaceutical Company Inc. Announces Initiation of Clinical Trial for Investigational PYY3-36 Nasal Spray Under Co-Development and Co-Promotion ... Pay-Per-View - PR Newswire - HighBeam Research Feuerstein's Biotech Mailbag - Feb 3, 2007 By Adam Feuerstein. Welcome to the "biotech mailbag." I get a lot of great reader email and feedback -- keep the email coming -- which I try hard to answer ... TheStreet.com - TheStreet.com (subscription) Article: NASTECH SEALS DEAL WITH P&G - SHARES JUMP A … - Feb 2, 2006 NASTECH SEALS DEAL WITH P&G - SHARES JUMP A MULTIMILLION-DOLLAR LINKUP ON OSTEOPOROSIS NASAL SPRAY.(Business) ... find Seattle Post-Intelligencer (Seattle, ... Pay-Per-View - Seattle Post-Intelligencer - HighBeam Research Press Release: Nastech Announces Presentation of Scientific Abstracts... - Nov 2, 2006 Nastech Announces Presentation of Scientific Abstracts at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nastech Completes Enrollment of Phase 2 Clinical Trial... - Jan 8, 2008 Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Selected biotechnology, biotech-related, small-molecule and other FDA... - Feb 27, 2006 Spray Nasal Spray treats postmenopausal (calcitonin salmon) osteoporosis in ... vaccine) FORTICAL Nasal SprayAug 2005 (calcitonin salmon) GAMMAGARD Apr ... Pay-Per-View - Chain Drug Review - HighBeam Research Nastech Announces Presentation of Scientific Abstracts at the... - Nov 2, 2006 BOTHELL, Wash., Nov. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. announced the presentation of two abstracts this week at the American ... Free with registration - PR Newswire - AccessMyLibrary.com Unigene and Upsher-Smith File Patent Infringement Lawsuit against … - Jul 25, 2006 Unigene Laboratories, Inc. (OTCBB: UGNE) and Upsher-Smith Laboratories, Inc. have jointly filed in the US District Court for the Southern District of New ... Genetic Engineering News - Genetic Engineering News (press release) Nastech, P&G Add Study, Amend Osteoporosis Deal - Dec 6, 2006 The company received a not-approvable letter in July for its generic intranasal calcitonin-salmon formulation to treat osteoporosis due to an FDA concern of ... BioWorld Online - BioWorld Online Article: REGIONAL NEWS: NASTECH TO EXPAND TRIALS OF INSULIN … - Sep 27, 2007 REGIONAL NEWS: NASTECH TO EXPAND TRIALS OF INSULIN NASAL SPRAY.(Business) ... find Seattle Post-Intelligencer (Seattle, WA) articles. Pay-Per-View - Seattle Post-Intelligencer - HighBeam Research NASTECH RESPONDS TO FDA LETTER FOR NASAL SPRAY ANDA - Oct 3, 2006 Nastech Pharmaceutical announced it has submitted a complete response to the not approvable letter from the FDA for its abbreviated new drug application ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Press Release: Nastech Pharmaceutical Company Inc. Provides Update … - Dec 4, 2006 Nastech Pharmaceutical Company Inc. Provides Update on Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nastech Submits Investigational New Drug Application... - Jun 7, 2006 Nastech Submits Investigational New Drug Application for PYY3-36 Nasal Spray to Treat Obesity. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nastech Initiates Dose Ranging Study of PYY(3-36)... - Aug 14, 2006 Nastech Initiates Dose Ranging Study of PYY(3-36) Nasal Spray for Obesity. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research FDA OKs Nastech's osteo spray production site.(Nastech Pharmaceutical... - Mar 6, 2006 USA-based Nastech Pharmaceutical has completed the Food and Drug Administration's pre-approval inspection of its Bothell, Washington, facility which enables ... $4.95 - Pharma Marketletter - ECNext Osteoporosis; Recent studies add new data to osteoporosis research - Mar 28, 2006 Keywords: Cincinnati, Ohio, United States, Alendronate, Bone Mineral Density, Calcitonin Salmon, Postmenopausal Women, Osteoporosis, Pharmacotherapy, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: NASTECH'S NASAL SPRAY ALTERNATIVE TO APPROVED … - Aug 1, 2006 NASTECH'S NASAL SPRAY ALTERNATIVE TO APPROVED INJECTED PRODUCT. ... find Biotech Business articles. In a preliminary Phase I clinical trial, a nasal spray ... Pay-Per-View - Biotech Business - HighBeam Research Press Release: Nastech Pharmaceutical Company Inc. and Procter & … - Feb 1, 2006 Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Nastech Enters Into Supply Agreement with Procter & … - Jun 6, 2006 Nastech Enters Into Supply Agreement with Procter & Gamble for Parathyroid Hormone (PTH1-34) Nasal Spray. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Women's : Menopause And Osteoporosis Treatment - Dec 19, 2007 ...(Prudent Press Agency) Menopause is simply the name given to the last menstrual period. Menopause is characterized by the loss of estrogen production by the ... prudentpressagency.com Generic drugs' quick, simple route to market has many roadblocks - Apr 13, 2008 By JOSEPH TARTAKOFF. For almost three years now, a mystery company has foiled Nastech Pharmaceutical's hopes of bringing its first product to market. ... Seattle Post-Intelligencer - Seattle Post Intelligencer Generic biologics still on radar screen in Congress.(Practice Trends) - Mar 1, 2007 Hylenex (hyaluronidase recombinant human), Hydase and Amphadase (hyaluronidase), and Fortical (calcitonin salmon recombinant) nasal spray. ... Free with registration - Internal Medicine News - AccessMyLibrary.com Highlights of rising and falling US stocks - MarketWatch - Jul 13, 2006 By MarketWatch. Cascade Bancorp shares rose 7.5% Thursday after the company reported second-quarter net income of 41 cents a share from 28 cents in the ... MarketWatch HLYS, LCAV, LGCY, NSTK, XFML, ARGA Have Also Been Added To … - Nov 9, 2007 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Heelys Inc. ... Free with registration - M2 Presswire - AccessMyLibrary.com PulseClinical: NEED TO KNOW - METABOLIC BONE DISEASE. - Jun 28, 2007 ...* There is evidence that adequate calcium intake and vitamin D status in peri- and postmenopausal women may reduce bone loss but there is no good evidence ... Free with registration - Pulse - AccessMyLibrary.com Upsher-Smith Laboratories Disappointed in FDA's Decision to Delay … - Jul 18, 2005 MINNEAPOLIS, July 18 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., a Minnesota-based pharmaceutical company, expressed disappointment today the FDA's ... RedOrbit Article: 3RD ROUND OF JOB CUTS AT BOTHELL BIOTECH FIRM … - Aug 5, 2008 3RD ROUND OF JOB CUTS AT BOTHELL BIOTECH FIRM PRESIDENT AMONG THOSE LET GO AS MDRNA REDEFINES.(Business) ... find Seattle Post-Intelligencer (Seattle, ... Pay-Per-View - Seattle Post-Intelligencer - HighBeam Research Guru Alerts for Friday, November 4, 2005 SNRG, MOBL, DOIG, UGNE. - Nov 4, 2005 Dallas, Texas - Stock Guru Alerts for Friday include SNRG Corporation (OTCBB: SNRG), MobilePro Corp. (OTCBB: MOBL), Delta Oil & Gas, Inc. (OTCBB: DOIG) and ... Free with registration - M2 Presswire - AccessMyLibrary.com As First Step In Biogeneric Debate, Omnitrope Cleared - Jun 1, 2006 Prima Pharm Inc., and Amphastar Pharmaceuticals Inc., respectively) and Fortical (calcitonin salmon recombinant, from Unigene Laboratories Inc.). ... BioWorld Online - BioWorld Online Hurdles block generic drugs - Feb 13, 2006 By Benjamin J. Romano. They compete with patented, brand-name counterparts, often driving down prices dramatically within weeks of coming on the market. ... Seattle Times NSTK, PRXI, SEED, DCFF, EXCS, WSZL Have Also Been Removed From … - Dec 6, 2007 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Nastech ... $4.95 - M2 Presswire - ECNext BioWorld Today - Aug 26, 2005 By Karen Pihl-Carey. Only a few weeks after withdrawing one public offering due to market conditions, Nastech Pharmaceutical Company Inc. did a complete ... BioWorld Online - BioWorld Online Article: Better taste helps the medicine go down.(Adams Respiratory … - Mar 5, 2007 Better taste helps the medicine go down.(Adams Respiratory Therapeutics Inc. introduces Mucinex line of cold remedies)(Insight Pharmaceuticals Corp. Pay-Per-View - Chain Drug Review - HighBeam Research Spray OK'D - Sep 5, 2005 Unigene Laboratories won FDA approval last week to begin marketing a nasal spray as a treatment for post-menopausal women suffering from osteoporosis. ... RedOrbit Article: DRUG CAPSULE WHAT YOU SHOULD KNOW - The Milwaukee … - Dec 11, 2006 DRUG CAPSULE WHAT YOU SHOULD KNOW ... find The Milwaukee Journal Sentinel articles. SUMATRIPTAN NASAL SPRAY What it does: This nasal spray is used to treat ... Pay-Per-View - Milwaukee Journal Sentinel - HighBeam Research KSP, SHA, ANSW, NSTK, REFR, ZVUE Have Been Removed From … - Oct 19, 2007 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: K-Sea ... $4.95 - M2 Presswire - ECNext ALSO NOTED: Able Labs files Ch. 11; Vertex wins fast track; Tamiflu … - Jul 18, 2005 ...> US government researchers say they've shown in mice tests that Tamiflu suppresses the avian flu strain now rampant in poultry in Vietnam, Cambodia, ... FierceBiotech Biopharmaceuticals: approval trends in 2005: in 2005, 10 … - Aug 1, 2006 To date, about 165 biopharmaceuticals have gained marketing approval in the United States or Europe; approximately one in every four drugs introduced on the ... $4.95 - Biopharm International - ECNext Biosimilar or generic? - Jul 19, 2006 ..."Unlike with epoetin, calcitonin-salmon is not the same as the human form so any antibodies it creates in the body do not target native calcitonin," Brandt ... In-PharmaTechnologist.com Press Release: Nastech Pharmaceutical Company Announces Initiation … - Sep 26, 2007 Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research OTCR Morning Alerts for Thursday, October 27, 2005 MIVT, PTSC, IGPG, ... - Oct 27, 2005 Dallas, Texas - OTCR Morning Alerts for Thursday include MIV Therapeutics Inc. (OTCBB: MIVT), Patriot Scientific Corporation (OTCBB: PTSC), Ignis Petroleum ... Free with registration - M2 Presswire - AccessMyLibrary.com Article: Generic biologics still on radar screen in Congress.(Practice... - Mar 1, 2007 Hylenex (hyaluronidase recombinant human), Hydase and Amphadase (hyaluronidase), and Fortical (calcitonin salmon recombinant) nasal spray. ... Pay-Per-View - Internal Medicine News - HighBeam Research Guru Alerts for Friday, October 21, 2005 - QTEK, UGNE, UGHO, RWNW. - Oct 21, 2005 Dallas, Texas - Stock Guru Alerts for Friday include Quintek Technologies, Inc. (OTCBB: QTEK), Unigene Laboratories, Inc. (OTCBB: UGNE), Universal Guardian ... Free with registration - M2 Presswire - AccessMyLibrary.com Nastech Announces Third Quarter 2006 Financial Results. - Nov 1, 2006 BOTHELL, Wash., Nov. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. today reported financial results for the three- and nine-month periods ... Free with registration - PR Newswire - AccessMyLibrary.com FDA under pressure to 'open the floodgates' for biogenerics - Aug 17, 2006 ...turned down Nastech's generic version of the nasal spray Miacalcin (calcitonin salmon), refusing to treat the protein-based drug as a normal generic. ... In-PharmaTechnologist.com TwinTrader.com Reports on OTCBB Dollar Volume Movers and Focus … - Jul 27, 2006 TwinTrader.com reports on the OTCBB Dollar Volume Movers: SHQC, RESE, NTPA, ECPN, VCSL, and Focus Stock of the Day NEXH. To enroll your publicly-traded ... Free with registration - M2 Presswire - AccessMyLibrary.com Nastech leads drug stock downward. - Jul 13, 2006 BOSTON (MarketWatch) -- Nastech Pharmaceuticals lead drug stocks downward early Thursday, as shares of the drug developer sank on news that regulators do ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com StreetInsider.com Pre-Open Movers 07/13 - Jul 13, 2006 Sento Corp. (Nasdaq: SNTO) 48% LOWER; expects to report consolidated revenues in the range of $14.4 to $14.6 million, an operating loss of $1.5 to $1.6 ... StreetInsider.com - StreetInsider.com (subscription) Nastech Pharmaceutical (NSTK) SqueezeTrigger Price Is $12.30. Short … - Dec 22, 2005 BUYINS.NET, www.buyins.net, announced today that the 1.34 million shares declared short on Nastech Pharmaceutical (NASDAQ: NSTK) have a SqueezeTrigger Price ... Free with registration - M2 Presswire - AccessMyLibrary.com Nastech's oesteoporosis ANDA rejected by FDA. - Jul 24, 2006 Nastech's oesteoporosis ANDA rejected by FDA. US drugmaker Nastech Pharmaceutical says that the Food and Drug Administration has said that its Abbreviated ... $9.94 - Pharma Marketletter - Alacra Store Cancer Therapy; Hook effect in calcitonin immunoradiometric assays... - Apr 4, 2006 2006 APR 4 - (NewsRx.com) -- A phenomenon known as the hook effect in calcitonin immunoradiometric assays can alter prognosis in patients with medullary ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Calcitonin nasal spray may preserve bone microarchitecture in older … - Jul 15, 2005 Calcitonin nasal spray may preserve bone microarchitecture in older women.(Rheumatology) ... find Internal Medicine News articles. BETHESDA, MD. Pay-Per-View - Internal Medicine News - HighBeam Research Article: Nasal Spray Bottles.(NEW PRODUCTS) - Surgical Products | … - Feb 1, 2008 Nasal Spray Bottles.(NEW PRODUCTS) ... find Surgical Products articles. [ILLUSTRATION OMITTED] EPS now offers 25-ml Nasal Spray Bottles. Pay-Per-View - Surgical Products - HighBeam Research Press Release: Non-Drug Alternative To Cold Medications for Children... - Jan 15, 2007 Non-Drug Alternative To Cold Medications for Children Is As Close As Your Local Pharmacy. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research FDA Approves Fortical, Unigene's Nasal Calcitonin Product for … - Aug 15, 2005 ...for Fortical(R) calcitonin-salmon (rDNA origin) Nasal Spray, its patented nasal calcitonin product for the treatment of postmenopausal osteoporosis. ... $4.95 - Business Wire - ECNext Unigene Begins Media Education Initiative to Promote Bone Health; CEO... - Mar 31, 2006 FAIRFIELD, NJ -- Warren Levy, Ph.D., President and CEO of Unigene Laboratories, Inc. (OTCBB: UGNE), was interviewed by television stations across the ... $4.95 - Business Wire - ECNext Breast Cancer; Breast cancer inhibited by calcitonin - May 17, 2006 ..."There is a growing body of evidence indicating that CT and calcitonin receptor (CTR) are involved in the regulation of cell growth, differentiation, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Progressive Following on Sepracor, Inc. - M2 Presswire... - Apr 17, 2008 Progressive Following on Sepracor, Inc. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Countering Colds With Common Sense. - PR Newswire | … - Sep 19, 2007 Countering Colds With Common Sense. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Nastech Announces Second Quarter 2006 Financial Results. - Aug 2, 2006 BOTHELL, Wash., Aug. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. today reported financial results for the three- and six-month periods ... $4.95 - PR Newswire - ECNext FDA APPROVES FORTICAL FOR POSTMENOPAUSAL OSTEOPOROSIS - Aug 16, 2005 Unigene Laboratories has received approval from the FDA for Fortical calcitonin-salmon (rDNA origin) nasal spray, its patented nasal calcitonin product for ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones FDA approves Unigene's osteoporosis drug.(TUESDAY, AUGUST 16) - Aug 22, 2005 More than two years after filing a new drug application for Fortical, Unigene Laboratories Inc. received final FDA approval for the osteoporosis product. ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Nastech Announces Fourth Quarter and Full Year 2005 Financial Results. - Mar 15, 2006 BOTHELL, Wash., March 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. , a leader in developing therapeutics using advanced molecular ... $4.95 - PR Newswire - ECNext Patanase nasal spray, Relistor.(NEW & APPROVED)(Drug overview) | … - Jun 1, 2008 Patanase nasal spray, Relistor.(NEW & APPROVED)(Drug overview) ... find Internal Medicine News articles. Patanase Nasal Spray (olopatadine HCI, ... Pay-Per-View - Internal Medicine News - HighBeam Research Press Release: StockGuru Price and Volume Alerts for Thursday July... - Jul 27, 2006 StockGuru Price and Volume Alerts for Thursday July 27, 2006 - One Company Launches New Cancer Screening While Another releases 2006 fiscal results. from M2 ... Pay-Per-View - M2 Presswire - HighBeam Research Guru Alerts for Wednesday, October 5, 2005 - EENT, UGNE, ASPN, SLPH … - Oct 5, 2005 Dallas, Texas - Stock Guru Alerts for Wednesday include Energy & Engine Technology Corporation (OTCBB: EENT), Unigene Laboratories, Inc. (OTCBB: UGNE), ... $4.95 - M2 Presswire - ECNext INTRANASAL DRUG DELIVERY - GIA- GLOBAL STRATEGIC BUSINESS … - May 1, 2008 Market Research, TF Market Research: INTRANASAL DRUG DELIVERY - GIA- GLOBAL STRATEGIC BUSINESS REPORT - 2008/05/01 - AlacraStore.com. $3,950.00 - GLOBAL INDUSTRY ANALYSTS SMALL & PRIVATE... - Alacra Store <P>This article has been removed and is no longer available.</P> | … - Mar 13, 2008 This article has been removed and is no longer available. ... find This article is unavailable articles. Pay-Per-View - Canadian Corporate News - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |